Company Overview of TRACON Pharmaceuticals, Inc.
TRACON Pharmaceuticals, Inc., a biopharmaceutical company, develops, licenses, and commercializes targeted therapies for cancer and age-related macular degeneration. Its products include TRC105, a human chimeric monoclonal antibody to CD105 that addresses multiple solid tumor types, including breast, kidney, prostate, ovarian, lung, liver, and bladder cancer; and TRC102, a small molecule inhibitor of base-excision repair, which is intended to reverse resistance to alkylator and antimetabolite chemotherapy, including agents used in the treatment of malignant melanoma, malignant glioma, and lung cancer. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to T...
8910 University Center Lane
San Diego, CA 92121
Founded in 2005
Key Executives for TRACON Pharmaceuticals, Inc.
Vice President of Product Development
Vice President of Clinical Operations
Compensation as of Fiscal Year 2014.
TRACON Pharmaceuticals, Inc. Key Developments
TRACON Pharmaceuticals Announces Executive Appointments
Sep 22 14
TRACON Pharmaceuticals announced that Paul Walker of NEA will join the TRACON board of directors and Bruce Steel of BioMed Ventures will join as a board observer. Paul Walker is a partner in NEA's Menlo Park Office. He is a board observer of Sunesis and Interleukin Genetics. Bruce Steel is the Managing Director of BioMed Ventures. The company also announced the appointment of Patricia Bitar as Chief Financial Officer. From November 2009 until April 2014, Ms. Bitar served in roles of increasing responsibility at NuVasive, Inc. serving most recently as Vice President and Corporate Controller.
TRACON Pharmaceuticals Initiates Phase 2 Clinical Trial of TRC105 in Patients with Soft Tissue Sarcoma
Sep 4 14
TRACON Pharmaceuticals announced the initiation of dosing in the Phase 2 portion of a clinical trial evaluating TRC105 in combination with Votrient(R) (pazopanib), a vascular endothelial growth factor (VEGF) inhibitor, to treat patients with soft tissue sarcoma. TRC105, an anti-endoglin antibody, is being studied in multiple clinical trials in combination with agents that inhibit angiogenesis by targeting the VEGF pathway. Dose escalation in the Phase 1 portion of the clinical trial of TRC105 in combination with Votrient has been completed and the combination was well-tolerated at the approved dose of Votrient and the recommended Phase 2 dose of TRC105. The Phase 2 portion of the trial is a multicenter, open-label, nonrandomized clinical trial of TRC105 in combination with Votrient in patients with soft tissue sarcoma. Approximately 60 patients are expected to be enrolled at approximately eight sites in the United States, including the sites that conducted the Phase 1 portion of the clinical trial: Mayo Clinic-Rochester, Mayo Clinic-Jacksonville, Duke University, Mount Sinai Hospital, Sarcoma Oncology Center-Santa Monica, and the University of Alabama-Birmingham. In the Phase 2 portion of the clinical trial, TRACON expects to correlate progression-free survival and overall response rate with endoglin expression on sarcoma tissue to assess whether direct endoglin expression on sarcoma cells may serve as a biomarker that identifies responsive sarcoma subtypes.
TRACON Pharmaceuticals Appoints William LaRue to its Board of Directors
Aug 4 14
TRACON Pharmaceuticals announced that it has appointed William LaRue to its Board of Directors effective immediately. Mr. LaRue will assume the position of chair of the audit committee. Mr. LaRue served as Senior Vice President, Chief Financial Officer and Treasurer of Cadence Pharmaceuticals from June 2006 until its acquisition by Mallinckrodt in March 2014.
Similar Private Companies By Industry
Recent Private Companies Transactions
September 22, 2014